Half-Fluence, Half-Dose Photodynamic Therapy: Less Direct Damage but More Inflammation?
Thomas Desmettre1, Martin A Mainster2, Gerardo Ledesma-Gil3
1Centre de Rétine Médicale, 187 rue de Menin, 59520 Marquette-Lez-Lille, France.
Pharmaceuticals (Basel, Switzerland)
|April 28, 2023
Summary
Half-fluence, half-dose verteporfin photodynamic therapy (PDT) can cause transient bacillary layer detachments (BALADs) in patients with retinal conditions. These BALADs resolved within weeks without causing photoreceptor damage in a small case series.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Photodynamic Therapy
Background:
- Half-fluence, half-dose (HFHD) verteporfin photodynamic therapy (PDT) is a modified treatment for neovascular eye conditions.
- Bacillary layer detachments (BALADs) are a potential, though not fully understood, complication of PDT.
